SCHEMBL6324737

SCHEMBL6324737

Cc1[nH]c(/C=C2\C(=O)Nc3cccc(-c4ccccc4-c4ccccc4)c32)c(C)c1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 4/20 0.56
FLT3 P36888 8/20 0.55
PDGFRB P09619 7/20 0.55
FGFR1 P11362 5/20 0.55
RET P07949 4/20 0.55
ABL1 P00519 1/20 0.55
KDR P35968 11/20 0.55
FLT4 P35916 5/20 0.55
KIT P10721 2/20 0.55
AURKB Q96GD4 4/20 0.50
AURKA O14965 3/20 0.50
FLT1 P17948 2/20 0.50
MAP4K2 Q12851 2/20 0.50
STK3 Q13188 2/20 0.50
PRKAA1 Q13131 2/20 0.50
AURKC Q9UQB9 2/20 0.50
MET P08581 2/20 0.50
GAK O14976 1/20 0.50
RPS6KA5 O75582 1/20 0.50
RPS6KA4 O75676 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321989 0.96 ALK (0.58) ALKFLT3PDGFRBFGFR1RET
SCHEMBL6321986 0.96 ALK (0.58) ALKFLT3PDGFRBFGFR1RET
SCHEMBL16090378 0.94 ALK (0.56) ALKFLT3PDGFRBFGFR1RET
SCHEMBL6322270 0.90 ALK (0.57) ALKFLT3PDGFRBFGFR1RET
SCHEMBL6321852 0.89 ALK (0.60) ALKFLT3PDGFRBFGFR1RET
SCHEMBL6320428 0.89 ALK (0.60) ALKFLT3PDGFRBFGFR1RET
SCHEMBL5829865 0.88 ALK (0.54) ALKFLT3PDGFRBFGFR1RET
SCHEMBL6322092 0.88 KDR (0.58) ALKFLT3PDGFRBFGFR1RET
SCHEMBL5829867 0.88 ALK (0.54) ALKFLT3PDGFRBFGFR1RET
SCHEMBL6320314 0.88 ALK (0.54) ALKFLT3PDGFRBFGFR1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 ALK 1015/4885FLT3 596/4885PDGFRB 575/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 ALK 1015/4885FLT3 596/4885PDGFRB 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.